Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Silexan in adults with mixed anxiety and depressive disorder
ISRCTN65844716Phase 3Completed
- Sponsor
- Schwabe Group
- Start
- Oct 2012
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in mixed anxiety-depressive disorder comparing Silexan with Placebo (2 arms). Primary endpoints: Change in Hamilton Rating Scale for Anxiety total score and Change in Montgomery-Asberg Depression Rating Scale total score. Started Oct 2012; status: completed.
02
Drugs
Silexan
03
Conditions
mixed anxiety-depressive disorder
Beyond the preview
Go deeper on ISRCTN65844716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN65844716.